About Aaryaman Aashind

Aaryaman is an accomplished journalist that’s passionate about providing in-depth insights regarding investing and personal finance. Recently he has been focused on the stock market and he specializes in evaluating high-growth stocks.

Prior to working as a financial writer, Aaryaman was a corporate lawyer advising on investment and debt-related transactions. He has worked on a variety of deals for both banks and private equity firms which have given him an appreciation of the nuances of the financial industry.


Recent Articles By Aaryaman Aashind

: DDOG |  News, Ratings, and Charts

4 Overvalued Stocks to Avoid for the Rest of 2020

Valuations for stocks such as Datadog (DDOG), DraftKings (DKNG), NovoCure (NVCR), and Chegg (CHGG) look stretched. The company's current and expected financials fail to justify their valuations. Its best to avoid these stocks for the remainder of this year.
: JNJ |  News, Ratings, and Charts

4 Major Stocks Reporting Earnings This Week

Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Wells Fargo (WFC), and Delta Air Lines (DAL) are all scheduled to release their quarterly results this week. These much-awaited earnings reports will inform investors on how the companies have performed over the last quarter and where the companies are headed this quarter.
: AMZN |  News, Ratings, and Charts

4 Stocks that Will Make New HIGHS in October    

Amazon.com (AMZN), Procter & Gamble (PG), Union Pacific (UNP), and Target (TGT) have done well so far this year and are on track to deliver an impressive continue topping earnings expectations. These companies are expected to achieve record earnings in the coming quarters despite the disruption caused by the pandemic. 
: WFC |  News, Ratings, and Charts

4 Dividend Stocks to AVOID in October 

Wells Fargo & Company (WFC), Kinder Morgan (KMI), Simon Property Group (SPG), and Annaly Capital Management (NLY) have reduced their dividend payouts due to pandemic-hit financials and expected pressure on the top line. So, it’s better to avoid these stocks for the time being.
: INFY |  News, Ratings, and Charts

4 Tech Stocks to Buy Before “Earnings Season”

Technology companies have not only performed well based on price appreciation, but many had earnings come in above expectations last quarter. As we enter the new earnings season, here are four stocks to consider before they report: Infosys Limited (INFY), Teradyne, Inc. (TER), LG Display Co. (LPL), and Netgear, Inc. (NTGR).
: MSFT |  News, Ratings, and Charts

4 Stocks with Double-Digit Dividend Growth

During volatile market conditions, stocks that provide capital appreciation and a steady stream of income over the long run are good bets. Microsoft (MSFT), UnitedHealth (UNH), JPMorgan Chase (JPM), and Walt Disney (DIS) are four stocks that have recorded double-digit dividend growth.
: ETSY |  News, Ratings, and Charts

4 TOP Growth Stocks to BUY Before 2021

Etsy (ETSY), PerkinElmer (PKI), Pool (POOL), and Deckers Outdoor (DECK) have gained significantly so far in 2020 based on their ability to capitalize on the pandemic. The long-term revenue and earnings growth potential of these companies should help their stocks perform even better in 2021.
: PG |  News, Ratings, and Charts

4 Stocks with a History of RAISING Dividends

Amid market volatility and uncertainties ahead of the presidential election, Procter & Gamble (PG), Abbott Laboratories (ABT), Lowe’s (LOW), and Target (TGT) are stocks worth considering due to dependable dividend income and an impressive history of dividend increases.
: PEP |  News, Ratings, and Charts

Coca-Cola vs. PepsiCo: Which Stock is a Better Buy?

The pandemic has resulted in the demand for soft drink to decline with restaurant traffic limited and live events on hold. However, it's likely that demand will return to normal once economies begin to reopen. Find out whether Pepsi (PEP) or Coke (KO) is the better buy.
: HZNP |  News, Ratings, and Charts

4 Growth Stocks set to SOAR in 2021

Horizon Therapeutics (HZNP), Exelixis (EXEL), Freshpet (FRPT), and Halozyme Therapeutics (HALO) are well-positioned to keep gaining in 2021 based on their earnings and revenue growth potential in hot sectors.
Page generated in 1.4479 seconds.